MT1 melatonin receptors and their role in the oncostatic action of melatonin

• Main Authors: Karolina Danielczyk, Piotr Dzięgiel
• Format: Article
• Language: English
• Published: Index Copernicus International S.A. 2009-09-01
• Series: Postępy Higieny i Medycyny Doświadczalnej
• Subjects: melatonina; błonowe receptory melatoninowe: MT1 i MT2; choroba nowotworowa
• Online Access: http://journals.indexcopernicus.com/fulltxt.php?ICID=894415

Melatonin, the main hormone produced by the pineal gland, strongly inhibits the growth of cancer cells [i]in vitro[/i] and [i]in vivo[/i]. Some publications indicate that the addition of melatonin to culture medium slows the proliferation of some cancer cell lines. It is also suggested that melatonin used as an adjuvant benefits the effectiveness and tolerance of chemotherapy. The mechanisms of this are not fully understood, but melatonin receptors might be one of the most important elements. Two distinct types of membrane-bound melatonin receptors have been identified in humans: MT1 (Mel1a) and MT2 (Mel1b) receptors. These subtypes are 60�0homologous at the amino-acid level. MT1 receptors are G-protein-coupled receptors. Through the α subunit of G protein, melatonin receptors stimulate an adenylate cyclase and decrease the level of cAMP. This has a significant influence on cell proliferation and has been confirmed in many tests on different cell lines, such as S-19, B-16 murine melanoma cells, and breast cancer cells. It seems that expression of the MT1 melatonin receptors benefits the efficacy of melatonin treatment. Melatonin and its receptors may provide a promising way to establish new alternative therapeutic approaches in human cancer prevention.